Paclitaxel in the treatment of patients with anglosarcoma of the scalp or face Journal Article


Authors: Fata, F.; O'Reilly, E.; Ilson, D.; Pfister, D.; Leffel, D.; Kelsen, D. P.; Schwartz, G. K.; Casper, E. S.
Article Title: Paclitaxel in the treatment of patients with anglosarcoma of the scalp or face
Abstract: BACKGROUND. Angiosarcomas are rare tumors. Based on a complete response observed in a patient with angiosarcoma of the scalp treated with paclitaxel in a Phase II trial, the authors treated a cohort of patients with angiosarcoma of the scalp or face with paclitaxel as single agent. METHODS. The authors identified nine patients with angiosarcoma of the scalp or face treated at Memorial Sloan-Kettering Cancer Center with paclitaxel between January 1992 and December 1998. Various paclitaxel schedules were used over 1, 3, and 24 hours. RESULTS. Of the 9 patients, 8 had major responses (4 partial responses and 4 clinical complete responses) and 1 had a minor response, for a major response rate of 89%. The median duration of response was 5 months (range, 2-13 months). Neutropenia and peripheral neuropathy were the most frequent dose-limiting toxicities. No deaths were attributed to therapy. CONCLUSIONS. Paclitaxel as a single agent has substantial activity against angiosarcoma of the scalp or face, even in patients previously treated with chemotherapy or radiation therapy. Further investigation is warranted to define the optimal treatment dose and schedule.
Keywords: adult; cancer chemotherapy; clinical article; aged; middle aged; neutropenia; cancer localization; paclitaxel; skin neoplasms; facial neoplasms; peripheral neuropathy; antineoplastic agents, phytogenic; antineoplastic activity; angiosarcoma; hemangiosarcoma; scalp; face; humans; human; male; female; priority journal; article
Journal Title: Cancer
Volume: 86
Issue: 10
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1999-11-15
Start Page: 2034
End Page: 2037
Language: English
DOI: 10.1002/(sici)1097-0142(19991115)86:10<2034::aid-cncr21>3.0.co;2-p
PUBMED: 10570428
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Gary Schwartz
    385 Schwartz
  2. David G Pfister
    366 Pfister
  3. David H Ilson
    414 Ilson
  4. Eileen O'Reilly
    679 O'Reilly
  5. David P Kelsen
    524 Kelsen
  6. Ephraim S Casper
    108 Casper
  7. Farid T Fata
    7 Fata